NL-OMON50106
Withdrawn
Phase 2
Pan Tumor Study for Long Term Follow-up of Cancer Survivors Who Have Participated in Trials Investigating Nivolumab - BMS CA209-8TT: Pan tumor Nivolumab Rollover Study
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Bristol-Myers Squibb
- Enrollment
- 10
- Status
- Withdrawn
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\* Signed Written Informed Consent
- •\* Participants who have completed treatment with nivolumab, progressed on prior
- •nivolumab treatment or discontinued nivolumab due to toxicity, in the Parent
- •Study are not eligible to receive nivolumab in this study. These participants
- •may be enrolled for safety and survival follow\-up only.
- •\* Participant is eligible for nivolumab treatment as per the Parent Study
- •and/or Investigator assessed clinical benefit
Exclusion Criteria
- •For Participants planning to enter the study on nivolumab treatment:
- •\* Participant is not eligible for nivolumab treatment as per the Parent Study
- •\* Participants not receiving clinical benefit as assessed by the Investigator
- •(participant is still eligible for study if entering survival follow\-up only)
- •\* Any clinical adverse event (AE), laboratory abnormality, or intercurrent
- •illness which, in the opinion of the Investigator, indicates that participation
- •in the study is not in the best interest of the participant
- •\* History of allergy or hypersensitivity to study drug components
- •\* Prisoners or participants who are involuntarily incarcerated (Note: Under
- •certain specific circumstances and only in countries where local regulations
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Study to evaluate long-term safety of nivolumab for subjects with cancer who will be provided nivolumab or have finished treatment and are now in or have completed follow up on another study of nivolumab or nivolumab combinatiopan tumorMedDRA version: 20.0Level: LLTClassification code 10007050Term: CancerSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2018-004362-34-PTBristol-Myers Squibb International Corporation1,231
Active, not recruiting
Phase 1
Study to evaluate long-term safety of nivolumab for subjects with cancer who will be provided nivolumab or have finished treatment and are now in or have completed follow up on another study of nivolumab or nivolumab combinatiopan tumorMedDRA version: 20.0Level: LLTClassification code 10007050Term: CancerSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2018-004362-34-ESBristol-Myers Squibb International Corporation1,231
Active, not recruiting
Phase 1
Study to evaluate long-term safety of nivolumab for subjects with cancer who will be provided nivolumab or have finished treatment and are now in or have completed follow up on another study of nivolumab or nivolumab combinatiopan tumorMedDRA version: 20.0Level: LLTClassification code 10007050Term: CancerSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2018-004362-34-NLBristol-Myers Squibb International Corporation1,231
Active, not recruiting
Phase 1
Study to evaluate long-term safety of nivolumab for subjects with cancer who will be provided nivolumab or have finished treatment and are now in or have completed follow up on another study of nivolumab or nivolumab combinatioEUCTR2018-004362-34-NOBristol-Myers Squibb International Corporation1,231
Active, not recruiting
Phase 1
Study to evaluate long-term safety of nivolumab for subjects with cancer who will be provided nivolumab or have finished treatment and are now in or have completed follow up on another study of nivolumab or nivolumab combinatiopan tumorMedDRA version: 20.0Level: LLTClassification code 10007050Term: CancerSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2018-004362-34-GBBristol-Myers Squibb International Corporation1,231